Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009


    VANCOUVER, Aug. 28 /CNW/ - Cardiome Pharma Corp. (NASDAQ:   CRME / TSX:
COM) today announced that Dr. Christian Torp-Pedersen is scheduled to present
detailed findings from the Phase 2b clinical trial of vernakalant (oral) at
the European Society of Cardiology (ESC) Congress 2009, being held in
Barcelona, Spain from August 29 to September 2, 2009. The presentation, titled
"Oral vernakalant for the prevention of atrial fibrillation recurrence
post-cardioversion," is scheduled for Monday, August 31, 2009 at 4:45pm local
    Positive top-line results from the Phase 2b trial were originally
announced in July 2008. The 735-patient double-blind, placebo-controlled,
randomized, dose-ranging study was designed to explore safety and
tolerability, pharmacokinetics and efficacy of vernakalant (oral) over 90 days
of dosing in patients at risk of recurrent atrial fibrillation.
    Further information about ESC Congress 2009 can be found at

    About Cardiome Pharma Corp.

    Cardiome Pharma Corp. is a product-focused drug development company
dedicated to the advancement and commercialization of novel treatments for
disorders of the heart and circulatory system. Cardiome is traded on the
NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more
information, please visit our web site at

    Forward-Looking Statement Disclaimer

    Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including without
limitation statements containing the words "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar
expressions. Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements or information. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with the completion of clinical trials and
obtaining regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that:
we, together with our collaborative partners, may not be able to successfully
develop and obtain regulatory approval for vernakalant (iv) or vernakalant
(oral) in the treatment of atrial fibrillation or any other current or future
products in our targeted indications; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise additional
capital; we may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to establish
marketing and sales capabilities and the costs of launching our products may
be greater than anticipated; we rely on third parties for the continued supply
and manufacture of vernakalant (iv) and vernakalant (oral) and we have no
experience in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as described in
detail in our filings with the Securities and Exchange Commission available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to
place undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.

For further information:

For further information: Peter K. Hofman, Senior Director, Investor
Relations, (604) 676-6993 or Toll Free: 1-800-330-9928, Email:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890